THE ROLE OF ONCOTARGET

Oncotarget is a journal that was formed in 2010. At the beginning it dealt mainly with issues surrounding cancer treatment and examination referred to as Oncology. However, with time it grew to accommodate other fields of Biomedicine. The issues are published on a weekly basis and they are printed once demanded. The journal is found on the online platforms and can be accessed freely. They have progressed and made major strides of including other medical fields like cardiology, pharmacy, neuroscience and microbiology. Year after year the journal has been ranked to be the best in the market.

The professor of Oncology in the Cancer Institute of Roswell Park is Mikhail Blagosklonny. He also takes part in the scientific study of cancer and aging. This scientist is behind the formulation of TOR in aging and the use of a cancer drug referred to as rapamycin. Mikhail Blagosklonny graduated from the First Pavlov State Medical University of St. Petersburg. In 2002 he became an associate professor at the Network Medical College and later took the position of a senior scientist at Ordway Research Institute. His research is mainly based on two elements one is the cancer therapy which largely protect the normal skin from any damage, and the main mechanisms associated with aging and anti-aging drugs. He is the chief editor of Aging, Oncotarget and Cell Cycle. Moreover, he is one of editorial board of Cell Death and Differentiation and also involved in cancer biology and therapy. Follow Mikhail on Loop

The Oncotarget’s success is based on the qualified and passionate editors, the use of different online platforms which is widely used and the various strategies they use while publishing. The editors look careful at the manuscripts and evaluate them without looking at the race, citizenship or religious believes of the authors. Similarly, the decision on publication is not in any way political. The editorial team does not give any information outside the editorial board. All the information is confidential and the editors are not subjected to use the unpublished information. Another task for the editors is to look keenly at the manuscripts. On the other side peer review is of great importance since it guides the editors in decision making and to review on the work of the authors and identify where they are supposed to improve on. Visit ResearchGate.Net to learn more about Mikhail’s latest work.

ONCOTARGET MAKES BIOMEDICAL RESEARCH EASIER

With the advancement in technology, the internet has become one of the most resourceful places for people. Rich with vast information from all sectors of the economy, the internet has continued to contribute immensely to research both academic and professional. If you are a researcher, one of the challenges you may have experienced is limited access to some of the sources. You find yourself searching on a search engine and finding an article. When you follow it up, you only find an abstract and more buttons to sign up or pay up and it is just frustrating.

For biomedical researchers, Oncotarget is giving you free access to the most recent research papers. Oncotarget is an online weekly journal that contains freely accessible peer reviewed journal articles. These articles are from the various biomedical sub-disciplines such as oncology, endocrinology, neuroscience and others. The journal offers an easy to use user-friendly interface. It also has an extensive search engine enabling researchers to quickly find the articles of their interest. The articles are also quite reliable given that they are peer reviewed and edited by a competent team led by the editors in chief. Read more http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget

Oncotarget was established in 2010 with an aim to make new discoveries in biomedicine known quickly among professionals in the biomedical field, biomedical students and interested members of the public. As such, it gives room for numerous authors to publish their work. Some authors have had their papers rejected by other journals but Oncotarget reaches to them as well. Such an author gets a second opinion and possibly a publishing of their paper when the team at Oncotarget evaluates the rejected paper. Oncotarget only requires the rejected paper, comments from the other journal and the rebuttal letter.

Mikhail Blagosklonny is one of the editors in chief of Oncotarget. He is passionate about Biomedicine with particular interest in cancer, molecular and cellular Biology, aging and other clinical investigations. He is a professor of oncology at the Roswell Park Cancer Institute in Buffalo, New York. Blagosklonny began his career as an associate professor of medicine in New York Medical College. He has worked in other organizations ever since and has acquired massive knowledge over the time. He is also an author with about 250 peer reviewed articles. Download output styles at Endnote.com.